Literature DB >> 20692871

Pathological complete response: still a relevant endpoint in rectal cancer?

Yu Jo Chua.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20692871     DOI： 10.1016/S1470-2045(10)70189-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

Review 1.  Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.

Authors:  Lorenzo Fornaro; Chiara Caparello; Caterina Vivaldi; Virginia Rotella; Gianna Musettini; Alfredo Falcone; Editta Baldini; Gianluca Masi
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

2.  Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.

Authors:  Vaneja Velenik; Janja Ocvirk; Maja Music; Matej Bracko; Franc Anderluh; Irena Oblak; Ibrahim Edhemovic; Erik Brecelj; Mateja Kropivnik; Mirko Omejc
Journal:  Radiat Oncol       Date:  2011-08-31       Impact factor: 3.481

3.  A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

Authors:  Ramon Salazar; Jaume Capdevila; Berta Laquente; Jose Luis Manzano; Carles Pericay; Mercedes Martínez Villacampa; Carlos López; Ferran Losa; Maria Jose Safont; Auxiliadora Gómez; Vicente Alonso; Pilar Escudero; Javier Gallego; Javier Sastre; Cristina Grávalos; Sebastiano Biondo; Amalia Palacios; Enrique Aranda
Journal:  BMC Cancer       Date:  2015-02-26       Impact factor: 4.430

4.  Tumor regression in rectal cancer after intensified neoadjuvant chemoradiation: a morphometric and clinicopathological study.

Authors:  Friedrich Prall; Oliver Schmitt; Leif Schiffmann
Journal:  World J Surg Oncol       Date:  2015-04-21       Impact factor: 2.754

5.  Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.

Authors:  K J Gash; A C Chambers; D E Cotton; A C Williams; M G Thomas
Journal:  Br J Cancer       Date:  2017-06-22       Impact factor: 7.640

Review 6.  Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Authors:  Thomas J George; Carmen J Allegra; Greg Yothers
Journal:  Curr Colorectal Cancer Rep       Date:  2015
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.